Jean–Luc Van Laethem

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

Eric Van Cutsem, Marc Peeters, Salvatore Siena et al. · Journal of Clinical Oncology · 2007 · 2K citations

Medicine, Oncology, Pharmacology +14

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab

Bart Jacobs, Wendy De Roock, Hubert Piessevaux et al. · Journal of Clinical Oncology · 2009 · 368 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer

Josep Tabernero, Eric Van Cutsem, Eduardo Díaz‐Rubio et al. · Journal of Clinical Oncology · 2007 · 337 citations

Medicine, Oncology, Pharmacology +14

Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study

Jean–Luc Van Laethem, Pascal Hammel, F. Mornex et al. · Journal of Clinical Oncology · 2010 · 295 citations · Full text

Medicine, Oncology, Surgery +17